Sexology and the pharmaceutical industry

The threat of co‐optation

Bibliographic Data

ID10208554
AuthorsLeonore Tiefer (New York University, corresponding author)
Year2000
Volume37
Issue3
Pages273-283
Publication date2000-08-01
Peer ReviewedYes
Open AccessNo
TypeARTICLE
VenueThe Journal of Sex Research (JOURNAL)
Journal identifiersISSN: 0022-4499 • E-ISSN: 1559-8519
PublisherTaylor & Francis (PUBLISHER • GB)
DOI10.1080/00224490009552048
OpenAlexW2082255742
LanguageEN
Citations received36
References cited40

In recent years, the pharmaceutical industry has become very interested in sex as a focus for drug development and marketing. Many sexologists have embraced this new trend, particularly because of greatly welcomed research funding and increased professional opportunities. However, this new relationship may be a Faustian bargain, and certainly raises serious ethical, political, theoretical, and research problems which must be openly discussed. This paper examines background elements which have led to this new science‐industry rapprochement, discusses research and publication problems which have arisen, analyzes conflicts between the models of sexuality favored by industry and sexology, and offers advice for preventing further erosion of sexology's liberatory mission despite the threats of commercialization

Commercialization · Human sexuality · Pharmaceutical industry · Political economy · Political science · Politics · Public relations · Sexology · Sociology · Law · Medicine · Pharmaceutical industry and healthcare · Reproductive Health and Contraception · Sexual function and dysfunction studies

Tools

Open DOISci-Hub